Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis FDA announced yesterday that guselkumab (Tremfya) is approved for use in pediatric patients moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA) in children six years and older https://t.co/GHjCgqHaJC